Nasus Pharma Ltd.
NSRX
Positions held
Your positionsNSRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $42.52M | Enterprise value | $30.80M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 3.87 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.2% | ROA | -96.7% | Debt / equity | 0.01 |
| Current ratio | 8.77 | Free cash flow | -$6.98M | Analyst recommendation | buy | Mean target | $19.67 |
| 52w high | $9.50 | 52w low | $1.98 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$5.9M | -$1.5M | -$1.1M | -$1.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$4.9M | -$1.1M | -$1.1M | -$2.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
2026-09-08 · Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 · Nasus Pharma Files $50 Million Shelf Registration
2026-08-21 · NSRX: First Half 2026 Financial Results
2026-08-21 · NSRX: First Half 2026 Financial Results
2026-08-19 · Nasus Pharma Announces Transition of Chief Financial Officer
2026-08-17 · Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Price (daily)
Full chart · RSI · MACD · patterns